CAP Partners LLC’s AbbVie ABBV Stock Holding History

CAP Partners LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,206	Closed	-$378K	–	131
2024 Q2	$378K	Sell	2,206 -26	-1%	-$4.31K	0.31%	79
2024 Q1	$406K	Sell	2,232 -6	-0.3%	-$1.03K	0.36%	68
2023 Q4	$347K	Buy	+2,238	New	+$326K	0.34%	67

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CAP Partners LLC's ABBV Position: Q3 2024 in Review

CAP Partners LLC sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 2,206 shares — an estimated $378K sold.

CAP Partners LLC first reported a position in ABBV in Q4 2023 and held it in 3 quarters. The position peaked at $406K in Q1 2024. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

CAP Partners LLC reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
CAP Partners LLC sold 2,206 AbbVie shares in Q3 2024, an estimated $378K.
CAP Partners LLC first reported a position in AbbVie in Q4 2023 and held it in 3 quarters.
CAP Partners LLC's AbbVie position peaked at $406K in Q1 2024.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on CAP Partners LLC's 13F filing for Q3 2024, filed 7 Nov 2024.